Dx Dialogues: The impact of next-generation sequencing on clinical utility
Sanjay Juneja, MD, talks through the impact of next-generation sequencing in both somatic and germline testing.
Transcript
Genetic testing now plays a central role in identifying inherited cancer risk and actionable tumor mutations.
[UPBEAT MUSIC] Next generation sequencing allows simultaneous analysis
of multiple genes, improving both efficiency and clinical utility efficiency because you
can check all of the things that may be incriminated or responsible for making that cancer a cancer, if it's a somatic test, or germline test
to see all of the things that can be playing a role on what you can expect the cancer to do or how to behave, as well as how to treat it.
The other part is the clinical utility, meaning not just for the treatments that are options that could vary if you have an inherited mutation,
but also, it can help you do clinical trials because we can study more of these molecular biomarkers or actionable biomarkers to see if additional therapies can
be either designed or more effective than current standard of care. [AUDIO LOGO]
cancer prevention
Browse videos by topic categories
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
ALL














